NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited ABN 64 079 319 314 (“Company“) will be held at KPMG, Level 36, Tower 2, Collins Square, 727 Collins Street, Melbourne, Victoria on Tuesday 21 November 2017 at 11am.
- Hexima completes enrolment for dose escalation stage of phase 1/2a clinical trial of HXP124 as a novel topical treatment for fungal nail infections
- Hexima Limited – Interim Financial Report for the 6 Months ended 31 December 2017
- Hexima doses first patient in phase 1/2a trial of HXP124 as a novel topical treatment for fungal nail infections
- Recruiting patients for fungal nail study
- VIDEO: CSO Marilyn Anderson interviewed by the AAS.